Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome | Zendy

Daniel J. Lewis | Zendy; Paul Haun | Zendy; Sara Samimi | Zendy; Carmela C. Vittorio | Zendy; Jennifer VillaseñorPark | Zendy; Stefan K. Barta | Zendy; Daniel J. Landsburg | Zendy; Jakub Svoboda | Zendy; Sunita D. Nasta | Zendy; Stephen J. Schuster | Zendy; Alain H. Rook | Zendy; Ellen J. Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome

Author(s) -

Daniel J. Lewis,

Paul Haun,

Sara Samimi,

Carmela C. Vittorio,

Jennifer VillaseñorPark,

Stefan K. Barta,

Daniel J. Landsburg,

Jakub Svoboda,

Sunita D. Nasta,

Stephen J. Schuster,

Alain H. Rook,

Ellen J. Kim

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.4901

Subject(s) - brentuximab vedotin , medicine , anaplastic large cell lymphoma , oncology , tolerability , mycosis fungoides , cd30 , lymphoma , surgery , gastroenterology , adverse effect

Treatment options for Sézary syndrome (SS) are limited and associated with low response rates. Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved for refractory CD30-positive cutaneous T-cell lymphoma. However, limited data exist on its efficacy in SS, including in the pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous T-Cell Lymphoma) trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research